乳腺小管癌和黏液癌HER-2基因扩增荧光原位杂交技术的检测  

Detecting HER-2 gene amplification by fluorescence in situ hybridization technique in tubular carcinoma and mucinous carcinoma of breast

作　　者：巴恩平[1] 李晓瑛[1] 吕亚莉[1] 赵坡[1] 

机构地区：[1]解放军总医院病理科,北京100853

出　　处：《中华肿瘤防治杂志》2013年第17期1319-1322,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:总结分析临床应用荧光原位杂交(fluorescence in situ hybridization,FISH)技术诊断乳腺小管癌和黏液癌表皮生长因子受体2(epidermal growth factor receptor 2,HER-2)基因扩增的经验和临床病理学意义。方法:用FISH和免疫组化技术诊断34例乳腺小管癌和黏液癌HER-2基因状态,分析HER-2基因扩增与HER-2蛋白表达以及临床病理的关系。结果:34例乳腺小管癌和黏液癌HER-2基因扩增阳性率为20.6%(7/34),其中小管癌为9.5%(2/21),黏液癌为38.5%(5/13),HER-2基因扩增多见于黏液癌,r=0.348,P=0.044。乳腺癌HER-2基因扩增与肿瘤大小(r=0.351,P=0.042)、淋巴结转移(r=0.815,P=0.000 1)、临床分期(r=0.549,P=0.001)和HER-2蛋白表达(r=0.361,P=0.036)呈正相关,HER-2基因扩增与与患者年龄无关,r=-0.072,P=0.687。结论:乳腺小管癌与黏液癌存在HER-2基因的扩增,临床应用FISH技术诊断HER-2基因扩增靶标来指导乳腺混合型黏液癌和小管癌的分子靶向治疗可能有助于改善患者的预后。OBJECTIVE： To summarize and analyze the experience and clinicopathological significance in application of flu- orescence in situ hybridization （FISH） technique in diagnosis of HER-2 gone amplification in uncommon tubular carcinoma and mucinous carcinoma of breast, and analyze the possible relationship between HER-2 gene amplification and type of tubular carcino- ma and mucinous carcinoma as well as clinicopathology. METHODS： Status of HER-2 gone amplification was diagnosed by FISH technique and analyzed with clincopathological data in 34 cases of tubular carcinoma and mucinous carcinoma of breast. RESULTS： The positive rate for HER-2 gene amplification was 20.6 % （7/34）, in which tubular carcinoma was 9.5% （2/21） and mucinous carcinoma was 38.5 % （5/13）, respectively. Amplification of HER-2 gene was correlative with the type of carcinoma（r = 0. 348, P=0. 044）, HER-2 protein expression （r= 0. 361, P= 0. 036）, tumor size （r= 0. 351, P = 0. 042）, lymph node metastasis （r= 0. 815 ,P=0. 000 1） ,and clinical stage （r=0. 549,P=0. 001） ,whereas not with age （r=-0. 072,P=0. 687）. CONCLUSIONS： HER-2 gene amplification may exist in the tubular type and the mucinous type of breast carcinoma. Clinical application of FISH technique to diagnose the target of HER-2 gene amplification and to direct molecular targeting therapy may obviously improve the prognosis in breast tubular and mucinous carcinoma patients. [

关 键 词：乳腺肿瘤 小管癌 黏液癌 表皮生长因子受体2 原位杂交 荧光 

分 类 号：R737.9[医药卫生—肿瘤]